Page last updated: 2024-08-26

hepsulfam and Acute Lymphoid Leukemia

hepsulfam has been researched along with Acute Lymphoid Leukemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Geller, RB; Grochow, LB; Janisch, L; Larson, RA; Milton, J; Ratain, MJ	1

Trials

1 trial(s) available for hepsulfam and Acute Lymphoid Leukemia

Article	Year
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Blast Crisis; Brain Diseases; Coma; Dose-Response Relationship, Drug; Electroencephalography; Female; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukopenia; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sulfonic Acids; Thrombocytopenia	1995

Article

Year

Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.

Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:3

Topics: Adult; Aged; Antineoplastic Agents; Blast Crisis; Brain Diseases; Coma; Dose-Response Relationship, Drug; Electroencephalography; Female; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukopenia; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sulfonic Acids; Thrombocytopenia

1995